Olivier Hermine

Olivier Hermine is a distinguished French hematologist and translational scientist whose dual expertise in T-cell lymphoma biology and mastocytosis pathophysiology has placed him at the frontier of two underserved areas of hematologic oncology. As Professor and Head of Adult Hematology at Hôpital Necker in Paris, he leads one of Europe's most productive research programs bridging basic immunology with clinical practice. His group has produced fundamental insights into T-cell receptor signaling, lymphocyte survival pathways, and the molecular mechanisms underlying mature T-cell neoplasms. In the field of mastocytosis—a clonal mast cell disorder driven largely by activating KIT D816V mutations—Hermine has made landmark contributions by elucidating disease biology and co-developing clinical trial frameworks that eventually led to the approval of avapritinib for advanced systemic mastocytosis. His laboratory work characterized KIT signaling downstream effectors and resistance mechanisms, directly informing drug development strategies. He is a founding contributor to the European Competence Network on Mastocytosis (ECNM) and has authored the principal French national guidelines for mastocytosis management. Hermine is equally active in lymphoma research, particularly for rare subtypes including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma (ATLL). He has investigated novel approaches such as interferon-alpha maintenance, histone deacetylase inhibitors, and combination targeted regimens. A prolific author and internationally sought lecturer, he has mentored numerous hematologists and immunologists across France and has received multiple national and European research prizes for his contributions to the molecular understanding and treatment of lymphoid malignancies.